1. Home
  2. CNSP vs VTAK Comparison

CNSP vs VTAK Comparison

Compare CNSP & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNS Pharmaceuticals Inc.

CNSP

CNS Pharmaceuticals Inc.

HOLD

Current Price

$6.04

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Logo Catheter Precision Inc.

VTAK

Catheter Precision Inc.

HOLD

Current Price

$2.30

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNSP
VTAK
Founded
2017
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
4.1M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
CNSP
VTAK
Price
$6.04
$2.30
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
73.0K
28.7K
Earning Date
11-17-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$730,000.00
Revenue This Year
N/A
$822.86
Revenue Next Year
N/A
$168.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
82.96
52 Week Low
$4.93
$1.49
52 Week High
$114.00
$15.68

Technical Indicators

Market Signals
Indicator
CNSP
VTAK
Relative Strength Index (RSI) 45.58 57.83
Support Level $5.75 $1.99
Resistance Level $7.51 $2.35
Average True Range (ATR) 0.72 0.12
MACD 0.09 0.04
Stochastic Oscillator 22.58 80.24

Price Performance

Historical Comparison
CNSP
VTAK

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Share on Social Networks: